Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.
Business Segments
A) India Branded Generics (33% in FY25):
The company is India’s largest pharmaceutical company, holding an 8.4% market share. Its product portfolio covers a range of therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain management, gynecology, etc.
It is the top-ranked company in prescriptions across 14 prescriber classes and a leader in the chronic segment, with 31 of its brands among India’s top 300 pharmaceutical brands.
b) Emerging Markets (18% in FY25):
The company deals in emerging markets, with a presence in 80+ countries worldwide, including key regions like Romania, Russia, South Africa, Brazil, and Mexico. It has a sales force of 2,900+ sales representatives across various markets.
Therapeutic Revenue Break-Up 9M FY29:
Neuro-Psychiatry: 19%,Cardiology: 17%,Gastroenterology: 14%,Diabetology: 9%,Pain/Analgesics: 7%,Others: 34%
Shareholding Pattern (March 2026)
Financial Summary
| Particular | Mar-22 | Mar-23 | Mar-24 | Mar-25 | Mar-26 |
| Sales – | 38,654 | 43,886 | 48,497 | 52,578 | 58,462 |
| Sales Growth % | 15.39% | 13.53% | 10.51% | 8.42% | 11.19% |
| Expenses + | 28,397 | 32,235 | 35,479 | 37,464 | 41,961 |
| Operating Profit | 10,258 | 11,650 | 13,018 | 15,114 | 16,501 |
| OPM % | 27% | 27% | 27% | 29% | 28% |
| Net Profit + | 3,389 | 8,513 | 9,610 | 10,965 | 11,509 |
| EPS in Rs | 13.64 | 35.32 | 39.91 | 45.55 | 47.84 |
| Dividend Payout % | 73% | 33% | 34% | 35% | 33% |
Synopsis of Financials
- Revenue: INR 145,598m (+13.6% YoY).
- Gross margin: 80.8% (up YoY) driven by “better product mix.”
- EBITDA: INR 39,542m (+6.4% YoY); EBITDA margin 27.1% (down YoY from 28.7% and down QoQ from 31.9%)
Final Outlook
Summary:
Sun Pharma continues to demonstrate strong business fundamentals supported by consistent revenue growth, healthy profitability, and leadership in the Indian pharmaceutical market. Its diversified product portfolio, expanding specialty business, and strong global presence provide a solid foundation for long-term growth. While the company remains financially strong with robust cash generation, increasing investments in global markets and product development may keep margins under some pressure in the near term. Overall, Sun Pharma remains one of the highest-quality pharmaceutical companies in India with stable long-term growth prospects.
Recent Performance (FY26 – View)
- FY26 Revenue increased to ₹58,462 Cr, up 11.9% YoY.
- Q4 FY26 Revenue grew 13.6% YoY.
- Gross Margin improved to 80.8% due to a better product mix.
- EBITDA increased 6.4% YoY, although margins softened because of higher spending and lower milestone income.
- The company continues to maintain a strong net cash position of US$3.2 billion, providing financial flexibility for future investments.
Sun Pharmaceutical Industries remains a fundamentally strong pharmaceutical company with a market-leading position, healthy cash flows, and consistent financial performance. The company is well placed to benefit from growing demand for branded generics and specialty medicines across domestic and international markets. However, after a strong run in the stock price, much of the near-term growth appears to be reflected in current valuations. Additionally, continued investments in specialty products and global expansion could keep margins volatile in the short term.
